Home  /  Resource Library  /  TISLELIZUMAB (BGB-A317) FOR RELAPSED/REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA: PRELIMINARY EFFICACY AND SAFETY RESULTS FROM A PHASE 2 STUDY

TISLELIZUMAB (BGB-A317) FOR RELAPSED/REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA: PRELIMINARY EFFICACY AND SAFETY RESULTS FROM A PHASE 2 STUDY

EHA 2020: Initial results of a phase II study investigating Tislelizumab for treatment of relapsed extranodal natural killer t-cell lymphoma.